Brief: Spectrum Pharmaceuticals Receives FDA Approval For Rolvedon Injection
09/09/2022 21:20
Sept 9 (Reuters) - Spectrum Pharmaceuticals Inc SPPI.O :
* SPECTRUM PHARMACEUTICALS RECEIVES FDA APPROVAL FOR
ROLVEDON
(EFLAPEGRASTIM-XNST) INJECTION
* SPECTRUM PHARMACEUTICALS INC - COMMERCIAL TEAM READY TO
LAUNCH
WITH PRODUCT AVAILABLE IN Q4
Source text for Eikon: ID:nBw8YxKH3a
Further company coverage: SPPI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Spectrum Pharmaceuticals
See all newsBrief: Assertio Holdings Announces Favorable Vote On Proposed Acquisition Of Spectrum Pharmaceuticals
Brief: Independent Proxy Advisory Firms ISS And Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “For” Proposed Deal With Assertio Holdings, Inc.
Brief: Spectrum Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement
U.S. RESEARCH ROUNDUP-CTI Biopharma, Park National, Playags
Spectrum Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary